Analyze Diet
Veterinary microbiology1987; 14(3); 337-342; doi: 10.1016/0378-1135(87)90121-0

Use of erythromycin-rifampin combination in treatment of Rhodococcus equi pneumonia.

Abstract: The selection of lipid-soluble antibiotics capable of intracellular penetration is considered critical for the successful treatment of Rhodococcus equi pneumonia and lung abscesses in foals. Two such antibiotics: erythromycin (25 mg kg-1, three times daily) and rifampin (5 mg kg-1 twice daily) have been used in combination for this purpose at the University of Florida since 1981. Positive evidence of R. equi was present on culture of tracheal aspirates in 57 foals, most of which exhibited radiographic evidence of extensive lung abscessation. The duration of therapy ranged from 4 to 9 weeks. Mild diarrhea was sometimes noted, but was never severe enough to require the termination of therapy. No other adverse side effects were apparent. Judged by a return of chest radiographs and hematologic parameters to normal, 50 of the 57 foals were considered to have recovered from the disease; a success rate of 88%.
Publication Date: 1987-08-01 PubMed ID: 3314109DOI: 10.1016/0378-1135(87)90121-0Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Clinical Trial
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article examines the efficacy of a combination treatment of erythromycin and rifampin in managing Rhodococcus equi pneumonia in foals. The study demonstrated an 88% success rate with this treatment approach.

Research Objectives and Methodology

  • The researchers aimed to determine if the lipid-soluble antibiotics erythromycin and rifampin, which are known for their intracellular penetration potential, could successfully treat Rhodococcus equi pneumonia and lung abscesses in foals.
  • The antibiotics were administered to foals diagnosed with R. equi pneumonia based on culture of tracheal aspirates. The foals were mostly those with radiographic indications of advanced lung abscessation.
  • The regimen was a combination of erythromycin (25 mg kg-1, thrice daily) and rifampin (5 mg kg-1, twice daily). This treatment method has been in practice at the University of Florida since 1981.

Results

  • The treatment duration varied between 4 and 9 weeks. Some cases of mild diarrhea were reported, but the reaction was never severe enough to warrant discontinuation of therapy. There were no other adverse side effects.
  • Upon the completion of therapy, recovery was primarily gauged by a return to regular chest radiographs and hematologic parameters. Based on these indicators, the researchers concluded that 50 out of the 57 foals had successfully recovered from the disease.
  • This translates to an efficacy or success rate of approximately 88%, demonstrating the potential of the erythromycin-rifampin combination therapy in treating R. equi pneumonia and lung abscesses in foals.

Significance and Implications

  • The findings of this research suggest that the combination of erythromycin and rifampin might be a viable treatment strategy for R. equi pneumonia in foals, particularly those with lung abscesses.
  • These results may also support further research into antibiotic therapies or combinations with potential intracellular activity against other bacterial infections in different hosts.

Cite This Article

APA
Hillidge CJ. (1987). Use of erythromycin-rifampin combination in treatment of Rhodococcus equi pneumonia. Vet Microbiol, 14(3), 337-342. https://doi.org/10.1016/0378-1135(87)90121-0

Publication

ISSN: 0378-1135
NlmUniqueID: 7705469
Country: Netherlands
Language: English
Volume: 14
Issue: 3
Pages: 337-342

Researcher Affiliations

Hillidge, C J
  • Department of Medical Sciences, College of Veterinary Medicine, University of Florida, Gainesville 32610.

MeSH Terms

  • Actinomycetales Infections / drug therapy
  • Actinomycetales Infections / veterinary
  • Animals
  • Animals, Newborn
  • Clinical Trials as Topic / veterinary
  • Drug Therapy, Combination
  • Erythromycin / therapeutic use
  • Horse Diseases / drug therapy
  • Horse Diseases / microbiology
  • Horses
  • Pneumonia / drug therapy
  • Pneumonia / microbiology
  • Pneumonia / veterinary
  • Rhodococcus
  • Rifampin / therapeutic use

Citations

This article has been cited 35 times.
  1. Hardefeldt L, Thomas K, Page S, Norris J, Browning G, El Hage C, Stewart A, Gilkerson J, Muscatello G, Verwilghen D, van Galen G, Bauquier J, Cuming R, Reynolds B, Whittaker C, Wilkes E, Clulow J, Burden C, Begg L. Antimicrobial prescribing guidelines for horses in Australia. Aust Vet J 2025 Dec;103(12):781-889.
    doi: 10.1111/avj.70003pubmed: 40903020google scholar: lookup
  2. Boneva-Marutsova B, Marutsov P, Kerner K, Zhelev G. First Detection of Rhodococcus equi in a Foal in Bulgaria-A Case Report. Animals (Basel) 2025 Jul 12;15(14).
    doi: 10.3390/ani15142058pubmed: 40723521google scholar: lookup
  3. Baptiste KE, Kyvsgaard NC, Ahmed MO, Damborg P, Dowling PM. Is Rifampin (Rifampicin) Essential for the Treatment of Rhodococcus equi Infections in Foals? A Critical Review of the Role of Rifampin. J Vet Pharmacol Ther 2025 Sep;48(5):345-358.
    doi: 10.1111/jvp.70007pubmed: 40552784google scholar: lookup
  4. Alvarez Narvaez S, Sanchez S. Exploring the Accessory Genome of Multidrug-Resistant Rhodococcus equi Clone 2287. Antibiotics (Basel) 2023 Nov 17;12(11).
    doi: 10.3390/antibiotics12111631pubmed: 37998833google scholar: lookup
  5. Rakowska A, Czopowicz M, Bereznowski A, Witkowski L. Investigation of the relationship between pulmonary lesions based on lung ultrasound and respiratory clinical signs in foals with suspected pulmonary rhodococcosis. Sci Rep 2023 Nov 8;13(1):19401.
    doi: 10.1038/s41598-023-46833-2pubmed: 37938262google scholar: lookup
  6. Knox A, Zerna G, Beddoe T. Current and Future Advances in the Detection and Surveillance of Biosecurity-Relevant Equine Bacterial Diseases Using Loop-Mediated Isothermal Amplification (LAMP). Animals (Basel) 2023 Aug 18;13(16).
    doi: 10.3390/ani13162663pubmed: 37627456google scholar: lookup
  7. Lord J, Carter C, Smith J, Locke S, Phillips E, Odoi A. Antimicrobial resistance among Streptococcus equi subspecies zooepidemicus and Rhodococcus equi isolated from equine specimens submitted to a diagnostic laboratory in Kentucky, USA. PeerJ 2022;10:e13682.
    doi: 10.7717/peerj.13682pubmed: 36164606google scholar: lookup
  8. Nielsen SS, Bicout DJ, Calistri P, Canali E, Drewe JA, Garin-Bastuji B, Gonzales Rojas JL, Gortázar C, Herskin M, Michel V, Miranda Chueca MÁ, Padalino B, Pasquali P, Roberts HC, Spoolder H, Ståhl K, Velarde A, Viltrop A, Winckler C, Baldinelli F, Broglia A, Kohnle L, Alvarez J. Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): antimicrobial-resistant Rhodococcus equi in horses. EFSA J 2022 Feb;20(2):e07081.
    doi: 10.2903/j.efsa.2022.7081pubmed: 35136423google scholar: lookup
  9. Patterson Rosa L, Mallicote MF, MacKay RJ, Brooks SA. Ion Channel and Ubiquitin Differential Expression during Erythromycin-Induced Anhidrosis in Foals. Animals (Basel) 2021 Nov 25;11(12).
    doi: 10.3390/ani11123379pubmed: 34944156google scholar: lookup
  10. Erol E, Scortti M, Fortner J, Patel M, Vázquez-Boland JA. Antimicrobial Resistance Spectrum Conferred by pRErm46 of Emerging Macrolide (Multidrug)-Resistant Rhodococcus equi. J Clin Microbiol 2021 Sep 20;59(10):e0114921.
    doi: 10.1128/JCM.01149-21pubmed: 34319806google scholar: lookup
  11. Álvarez-Narváez S, Huber L, Giguère S, Hart KA, Berghaus RD, Sanchez S, Cohen ND. Epidemiology and Molecular Basis of Multidrug Resistance in Rhodococcus equi. Microbiol Mol Biol Rev 2021 May 19;85(2).
    doi: 10.1128/MMBR.00011-21pubmed: 33853933google scholar: lookup
  12. Rakowska A, Cywinska A, Witkowski L. Current Trends in Understanding and Managing Equine Rhodococcosis. Animals (Basel) 2020 Oct 18;10(10).
    doi: 10.3390/ani10101910pubmed: 33081047google scholar: lookup
  13. Álvarez-Narváez S, Giguère S, Anastasi E, Hearn J, Scortti M, Vázquez-Boland JA. Clonal Confinement of a Highly Mobile Resistance Element Driven by Combination Therapy in Rhodococcus equi. mBio 2019 Oct 15;10(5).
    doi: 10.1128/mBio.02260-19pubmed: 31615959google scholar: lookup
  14. Giguère S, Berghaus LJ, Willingham-Lane JM. Antimicrobial Resistance in Rhodococcus equi. Microbiol Spectr 2017 Oct;5(5).
  15. Mir IA, Kumar B, Taku A, Bhardwaj RK, Bhat MA, Badroo GA. Prevalence and Antibiogram study of Rhodococcus equi in equines of Jammu and Kashmir, India. J Equine Sci 2015;26(1):21-4.
    doi: 10.1294/jes.26.21pubmed: 25829867google scholar: lookup
  16. Burton AJ, Giguère S, Berghaus LJ, Hondalus MK. Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice. Antimicrob Agents Chemother 2015;59(6):3633-6.
    doi: 10.1128/AAC.04941-14pubmed: 25824218google scholar: lookup
  17. Hildebrand F, Venner M, Giguère S. Efficacy of gamithromycin for the treatment of foals with mild to moderate bronchopneumonia. J Vet Intern Med 2015 Jan;29(1):333-8.
    doi: 10.1111/jvim.12504pubmed: 25619521google scholar: lookup
  18. Berghaus LJ, Giguère S, Guldbech K, Warner E, Ugorji U, Berghaus RD. Comparison of Etest, disk diffusion, and broth macrodilution for in vitro susceptibility testing of Rhodococcus equi. J Clin Microbiol 2015 Jan;53(1):314-8.
    doi: 10.1128/JCM.02673-14pubmed: 25378571google scholar: lookup
  19. Liu H, Wang Y, Yan J, Wang C, He H. Appearance of multidrug-resistant virulent Rhodococcus equi clinical isolates obtained in China. J Clin Microbiol 2014 Feb;52(2):703.
    doi: 10.1128/JCM.02925-13pubmed: 24478520google scholar: lookup
  20. Willsie-Ediger SK, Stanford JF, Salzman GA, Bamberger DM. Spectrum of disease caused by Rhodococcus equi in human immunodeficiency virus infection: Report of a case and review of the literature. Can J Infect Dis 1990 Fall;1(3):101-7.
    doi: 10.1155/1990/803153pubmed: 22553450google scholar: lookup
  21. Schlusselhuber M, Jung S, Bruhn O, Goux D, Leippe M, Leclercq R, Laugier C, Grötzinger J, Cauchard J. In vitro potential of equine DEFA1 and eCATH1 as alternative antimicrobial drugs in rhodococcosis treatment. Antimicrob Agents Chemother 2012 Apr;56(4):1749-55.
    doi: 10.1128/AAC.05797-11pubmed: 22232283google scholar: lookup
  22. Buckley T, McManamon E, Stanbridge S. Resistance studies of erythromycin and rifampin for Rhodococcus equi over a 10-year period. Ir Vet J 2007 Dec 1;60(12):728-31.
    doi: 10.1186/2046-0481-60-12-728pubmed: 21851690google scholar: lookup
  23. Venner M, Peters J, Höhensteiger N, Schock B, Bornhorst A, Grube M, Adam U, Scheuch E, Weitschies W, Rosskopf D, Kroemer HK, Siegmund W. Concentration of the macrolide antibiotic tulathromycin in broncho-alveolar cells is influenced by comedication of rifampicin in foals. Naunyn Schmiedebergs Arch Pharmacol 2010 Feb;381(2):161-9.
    doi: 10.1007/s00210-009-0481-1pubmed: 20012942google scholar: lookup
  24. Muscatello G, Gilkerson JR, Browning GF. Detection of virulent Rhodococcus equi in exhaled air samples from naturally infected foals. J Clin Microbiol 2009 Mar;47(3):734-7.
    doi: 10.1128/JCM.01395-08pubmed: 19144811google scholar: lookup
  25. Prescott JF, Machang'u R, Kwiecien J, Delaney K. Prevention of foal mortality due to Rhodococcus equi pneumonia on an endemically affected farm. Can Vet J 1989 Nov;30(11):871-5.
    pubmed: 17423454
  26. Asoh N, Watanabe H, Fines-Guyon M, Watanabe K, Oishi K, Kositsakulchai W, Sanchai T, Kunsuikmengrai K, Kahintapong S, Khantawa B, Tharavichitkul P, Sirisanthana T, Nagatake T. Emergence of rifampin-resistant Rhodococcus equi with several types of mutations in the rpoB gene among AIDS patients in northern Thailand. J Clin Microbiol 2003 Jun;41(6):2337-40.
  27. Jacks SS, Giguère S, Nguyen A. In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. Antimicrob Agents Chemother 2003 May;47(5):1742-5.
  28. Fines M, Pronost S, Maillard K, Taouji S, Leclercq R. Characterization of mutations in the rpoB gene associated with rifampin resistance in Rhodococcus equi isolated from foals. J Clin Microbiol 2001 Aug;39(8):2784-7.
  29. Sellon DC, Besser TE, Vivrette SL, McConnico RS. Comparison of nucleic acid amplification, serology, and microbiologic culture for diagnosis of Rhodococcus equi pneumonia in foals. J Clin Microbiol 2001 Apr;39(4):1289-93.
  30. Takai S, Takeda K, Nakano Y, Karasawa T, Furugoori J, Sasaki Y, Tsubaki S, Higuchi T, Anzai T, Wada R, Kamada M. Emergence of rifampin-resistant Rhodococcus equi in an infected foal. J Clin Microbiol 1997 Jul;35(7):1904-8.
  31. Morris AB, Brown RB, Sands M. Use of rifampin in nonstaphylococcal, nonmycobacterial disease. Antimicrob Agents Chemother 1993 Jan;37(1):1-7.
    doi: 10.1128/AAC.37.1.1pubmed: 8431003google scholar: lookup
  32. McNeil MM, Brown JM. The medically important aerobic actinomycetes: epidemiology and microbiology. Clin Microbiol Rev 1994 Jul;7(3):357-417.
    doi: 10.1128/CMR.7.3.357pubmed: 7923055google scholar: lookup
  33. Prescott JF. Rhodococcus equi: an animal and human pathogen. Clin Microbiol Rev 1991 Jan;4(1):20-34.
    doi: 10.1128/CMR.4.1.20pubmed: 2004346google scholar: lookup
  34. Nordmann P, Rouveix E, Guenounou M, Nicolas MH. Pulmonary abscess due to a rifampin and fluoroquinolone resistant Rhodococcus equi strain in a HIV infected patient. Eur J Clin Microbiol Infect Dis 1992 Jun;11(6):557-8.
    doi: 10.1007/BF01960815pubmed: 1526243google scholar: lookup
  35. Nordmann P, Kerestedjian JJ, Ronco E. Therapy of Rhodococcus equi disseminated infections in nude mice. Antimicrob Agents Chemother 1992 Jun;36(6):1244-8.
    doi: 10.1128/AAC.36.6.1244pubmed: 1416823google scholar: lookup